From GlobeNewswire: 2025-04-18 04:00:00

Valneva SE received an updated recommendation from the CDC’s ACIP for its single-dose chikungunya vaccine, IXCHIQ®, for individuals aged ≥18 traveling to outbreak areas. ACIP also noted a precaution for those aged ≥65 due to ongoing SAE investigation. Valneva supplied doses to France’s La Réunion for an outbreak. No new SAEs have been reported globally since January 2025. Valneva’s Chief Medical Officer emphasized the vaccine’s safety profile remains positive. The recommendation is pending final approval. Chikungunya is a mosquito-borne viral disease causing fever, joint pain, and fatigue, with significant global impact. Valneva specializes in developing prophylactic vaccines for infectious diseases.



Read more at GlobeNewswire: Valneva Provides Update on ACIP Recommendation for its